Mga Batayang Estadistika
| CIK | 1598696 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NeuroDerm Ltd.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2018 |
NDRM / NeuroDerm Ltd. / Redmile Group, LLC Passive Investment SC 13G/A 1 ndrm13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M74231107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) ý Rule 13d-1(b) ¨ Rul |
|
| October 30, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36737 NeuroDerm Ltd. (Exact name of registrant as specified in its char |
|
| October 18, 2017 |
As filed with the Securities and Exchange Commission on October 18, 2017 Registration No. |
|
| October 18, 2017 |
S-8 POS 1 tv477132s-8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 18, 2017 Registration No. 333-200331 Registration No. 333-205485 Registration No. 333-210497 Registration No. 333-217115 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-200331 POST-EFFECTIVE AMENDMENT |
|
| October 18, 2017 |
S-8 POS 1 tv477130s-8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 18, 2017 Registration No. 333-200331 Registration No. 333-205485 Registration No. 333-210497 Registration No. 333-217115 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-200331 POST-EFFECTIVE AMENDMENT |
|
| October 18, 2017 |
As filed with the Securities and Exchange Commission on October 18, 2017 Registration No. |
|
| October 18, 2017 |
As filed with the Securities and Exchange Commission on October 18, 2017 Registration No. |
|
| October 18, 2017 |
Mitsubishi Tanabe Pharma Corporation Completes acquisition of neuroderm Exhibit 99.1 FOR IMMEDIATE RELEASE October 18, 2017 Mitsubishi Tanabe Pharma Corporation Completes acquisition of neuroderm REHOVOT, ISRAEL, October 18, 2017 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, announced today the completion of the previously announced acquisition of NeuroDerm by Mi |
|
| October 18, 2017 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) 6-K 1 tv4770666k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number 001-36737 NEURODERM LTD. (Translation of registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Re |
|
| September 12, 2017 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number 001-36737 NEURODERM LTD. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 ( |
|
| September 12, 2017 |
NeuroDerm shareholders approve proposed acquisition by Mitsubishi Tanabe Pharma Corporation Exhibit 99.1 FOR IMMEDIATE RELEASE September 12, 2017 NeuroDerm shareholders approve proposed acquisition by Mitsubishi Tanabe Pharma Corporation REHOVOT, ISRAEL, September 12, 2017 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, announced that at NeuroDerm?s extraordinary general meeting of sh |
|
| September 11, 2017 |
Exhibit 99.1 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of Amendment No. 4 to Schedule 13G (including additional amendments thereto) with respect to the Ordinary Shares, par value NIS 0.01 per share, of NeuroDerm Ltd. This Joint Filing Agreement shall be filed as an Exhibit t |
|
| September 11, 2017 |
NDRM / NeuroDerm Ltd. / SCOPIA CAPITAL MANAGEMENT LP - SCHEDULE 13G/A Passive Investment SC 13G/A 1 e7564513ga.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M74231107 (CUSIP Number) August 31, 2017 (Date of Event Which Requires Filing of this Statement) Check t |
|
| August 17, 2017 |
Exhibit 99.1 NEURODERM LTD. 3 Pekeris St., Rabin Science Park Rehovot 7670212 Israel August 17, 2017 Dear NeuroDerm Ltd. Shareholders: We cordially invite you to attend an extraordinary general meeting of shareholders of NeuroDerm Ltd. (“NeuroDerm” or “we”) to be held at the principal executive offices of NeuroDerm, located at 3 Pekeris Street, Rabin Science Park, Rehovot 7670212, Israel, on Septe |
|
| August 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number 001-36737 NEURODERM LTD. (Translation of registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) |
|
| August 17, 2017 |
Exhibit 99.2 NEURODERM LTD. PROXY FOR EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 12, 2017 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Oded S. Lieberman and Roy Golan, and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to re |
|
| August 3, 2017 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2017 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) |
|
| August 3, 2017 |
Exhibit 99.1 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Second Quarter 2017 Financial Results REHOVOT, Israel ? August 3, 2017 ? NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced financial results for the se |
|
| August 1, 2017 |
Exhibit 99.1 FOR IMMEDIATE RELEASE August 1, 2017 NeuroDerm Announces EXTRAORDINARY General Meeting of Shareholders TO APPROVE ACQUISITION BY Mitsubishi Tanabe Pharma Corporation REHOVOT, ISRAEL, August 1, 2017 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it will hold an |
|
| August 1, 2017 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number 001-36737 NEURODERM LTD. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) |
|
| July 24, 2017 |
Exhibit 99.3 NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash REHOVOT, Israel ? July 24, 2017 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it has signed a definitive agreement under which Mitsubishi T |
|
| July 24, 2017 |
Exhibit 99.1 AGREEMENT AND PLAN OF MERGER by and among MITSUBISHI TANABE PHARMA CORPORATION MT PORTO LTD. and NEURODERM LTD. July 24, 2017 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 2 Section 1.1 Certain Definitions 2 Section 1.2 Additional Definitions 9 Section 1.3 Certain Interpretations 11 ARTICLE II THE MERGER 12 Section 2.1 The Merger 12 Section 2.2 The Closing 12 Section |
|
| July 24, 2017 |
NeuroDerm 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2017 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Addr |
|
| July 24, 2017 |
FORM OF VOTING AND SUPPORT AGREEMENT Exhibit 99.2 FORM OF VOTING AND SUPPORT AGREEMENT VOTING AND SUPPORT AGREEMENT (this ?Agreement?), dated as of July 24, 2017, by and among Mitsubishi Tanabe Pharma Corporation, a corporation formed under the laws of the State of Japan (?Parent?), MT Porto Ltd., a private company formed under the laws of the State of Israel and a wholly-owned subsidiary of Parent (?Merger Sub?), and the undersigned |
|
| June 30, 2017 |
Exhibit 99.1 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 Results of NeuroDerm’s ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology -Complete reduction of OFF-time to zero in 42% of patients treated for 24 hours; statistically significant and clinically meaningful reduction in OFF-time and |
|
| June 30, 2017 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2017 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Addr |
|
| June 9, 2017 |
European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial Exhibit 99.2 European Medicines Agency Accepts Design of NeuroDerm?s ND0612 Phase III iNDiGO Efficacy Trial REHOVOT, Israel ? June 6, 2017 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it has received a Scientific Advice Letter from the Scientific Advice Working Party of |
|
| June 9, 2017 |
Exhibit 99.3 NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson?s Disease and Movement Disorders - Includes demographic data from the ND0612 trial 006 and complete data from a Phase 1 pharmacokinetic study of ND0701 - REHOVOT, Israel ? June 8, 2017 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central ne |
|
| June 9, 2017 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2017 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Addr |
|
| June 9, 2017 |
Exhibit 99.1 NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders -ND0612H achieved a complete reduction of OFF-time to zero in 42% of patients treated for 24 hours - - Statistically significant and clinically meaningful reduction in OFF-time and increase in the portion of patients "ON" by |
|
| May 12, 2017 |
Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces First Quarter 2017 Financial Results REHOVOT, Israel ? May 11, 2017 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced financial results for th |
|
| May 12, 2017 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4668806k.htm FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2017 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Isr |
|
| April 3, 2017 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2017 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Add |
|
| April 3, 2017 |
Exhibit 99.1 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results - Files Annual Report on Form 20-F ? - Company to Host Conference Call and Webcast Today at 8:30 a.m. ET - REHOVOT, Israel ? March 30, 2017 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company dev |
|
| April 3, 2017 |
As filed with the Securities and Exchange Commission on April 3, 2017 Registration No. |
|
| March 29, 2017 |
Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Roy Golan, certify that: 1. I have reviewed this annual report on Form 20-F of NeuroDerm Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to |
|
| March 29, 2017 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Forms S-8 (No. 333-200331, No. 333-205485 and No. 333-210497) and F-3 (No. 333-210496) of NeuroDerm Ltd. of our report dated March 28, 2017 relating to the financial statements, which appears in this annual report on Form 20-F. Tel Aviv, Israel |
|
| March 29, 2017 |
Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Oded Lieberman, certify that: 1. I have reviewed this annual report on Form 20-F of NeuroDerm Ltd. (the ?company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit t |
|
| March 29, 2017 |
Exhibit 13.1 CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(b)/RULE 15d-14(b) UNDER THE EXCHANGE ACT AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of NeuroDerm Ltd. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2016 as filed with the S |
|
| March 29, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E |
|
| March 3, 2017 |
Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson?s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting - Trial 006 demonstrated a statistically significant and clinically meaningful reduction in OFF-time and increase in p |
|
| March 3, 2017 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2017 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Add |
|
| March 2, 2017 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-36737 NEURODERM LTD. (Translation of Registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) |
|
| February 14, 2017 |
NDRM / NeuroDerm Ltd. / SCOPIA CAPITAL MANAGEMENT LP - SCHEDULE 13G/A Passive Investment SC 13G/A 1 e7302813ga.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M74231107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 14, 2017 |
Exhibit 99.1 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of Amendment No. 3 to Schedule 13G (including additional amendments thereto) with respect to the Ordinary Shares, par value NIS 0.01 per share, of NeuroDerm Ltd. This Joint Filing Agreement shall be filed as an Exhibit t |
|
| February 14, 2017 |
NDRM / NeuroDerm Ltd. / Redmile Group, LLC Passive Investment neuroderm13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M74231107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) ý Rule 13d-1(b) ¨ Rule 13d-1( |
|
| February 1, 2017 |
Exhibit 99.1 NEURODERM Ltd. 3 Pekeris St., Rabin Science Park, Rehovot 7670212, Israel February 1, 2017 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 2, 2017 Dear NeuroDerm Ltd. Shareholders: We cordially invite you to attend an Extraordinary General Meeting of Shareholders, or the Meeting, of NeuroDerm Ltd., or the Company, to be held at 3:00 p.m. (Israel time) on Th |
|
| February 1, 2017 |
NeuroDerm 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2017 Commission File Number 001-36737 NEURODERM LTD. (Translation of Registrant?s name into English) Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel (Address of Principal |
|
| February 1, 2017 |
Exhibit 99.2 NEURODERM LTD. PROXY FOR EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 2, 2017 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Roy Golan and Yoav Shmaya, and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and |
|
| January 26, 2017 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2017 Commission File Number 001-36737 NEURODERM LTD. (Translation of Registrant?s name into English) Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel (Address of Principal |
|
| January 26, 2017 |
Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NEURODERM Announces EXTRAORDINARY General Meeting of Shareholders REHOVOT, ISRAEL, January 26, 2017 (GLOBE NEWSWIRE)?NeuroDerm Ltd. (NASDAQ: NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will hold |
|
| December 27, 2016 |
Exhibit 99.2 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Closing of Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares REHOVOT, Israel ? December 22, 2016 ? NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) dis |
|
| December 27, 2016 |
Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinson?s Disease - First evaluation of clinical efficacy of ND0612H in advanced Parkinson's patients ? REHOVOT, Israel, December 22, 2016 ? NeuroDerm Ltd. (Nasdaq: NDR |
|
| December 27, 2016 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4557486k.htm FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212 |
|
| December 8, 2016 |
Exhibit 99.2 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Pricing of a Follow-On Offering of Ordinary Shares REHOVOT, Israel ? December 7, 2016 ? NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the pricing of a follow-on |
|
| December 8, 2016 |
EX-99.1 4 v454679ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Launch of a Follow-On Offering of Ordinary Shares REHOVOT, Israel – December 6, 2016 – NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, to |
|
| December 8, 2016 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l ( |
|
| December 8, 2016 |
NeuroDerm Ltd. 4,000,000 Ordinary Shares (Par Value NIS 0.01 Per Share) UNDERWRITING AGREEMENT Exhibit 1.1 EXECUTION VERSION NeuroDerm Ltd. 4,000,000 Ordinary Shares (Par Value NIS 0.01 Per Share) UNDERWRITING AGREEMENT December 7, 2016 JEFFERIES LLC COWEN AND COMPANY, LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o COWEN AND COMPANY, LLC 599 Lexington Avenue, 27th Floor New York, New York 10022 Ladies and Gentlemen: Intro |
|
| December 8, 2016 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-210496 PROSPECTUS SUPPLEMENT (To the prospectus dated April 18, 2016) 4,000,000 Shares NeuroDerm Ltd. Ordinary Shares We are offering 4,000,000 ordinary shares. Our ordinary shares are listed on the NASDAQ Global Market under the symbol ?NDRM.? On December 5, 2016, the last reported sales price of our ordinary shares on the NASDAQ Global Market |
|
| December 6, 2016 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-210496 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not a |
|
| December 5, 2016 |
Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Top-Line Results of Pilot PK Trial Comparing ND0701 with Commercial Apomorphine ? Regulatory Development of ND0701 in the EU to Proceed Based on PK Similarity for the Treatment of Parkinson?s Disease ? REHOVOT, Israel, December 2, 2016 ? NeuroDerm Ltd. (Nasdaq: |
|
| December 5, 2016 |
NeuroDerm 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l ( |
|
| December 5, 2016 |
Exhibit 99.2 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm to Replace Two Phase 3 Clinical Trials with Small Pharmacokinetic Trials Following FDA Meeting on ND0612 Regulatory Development - Company to pursue comparative bioavailability regulatory route instead of clinical efficacy development route ? - NeuroDerm to add patients t |
|
| November 14, 2016 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l ( |
|
| November 14, 2016 |
NEURODERM LTD. CONDENSED INTERIM FINANCIAL INFORMATION September 30, 2016 Table of Contents Exhibit 99.2 NEURODERM LTD. CONDENSED INTERIM FINANCIAL INFORMATION (UNAUDITED) September 30, 2016 Table of Contents Page Index to Unaudited Financial Statements, as of September 30, 2016: Condensed Interim Statements of Financial Position F-2 Condensed Interim Statements of Comprehensive Loss F-4 Condensed Interim Statements of Changes in Shareholders' Equity F-5 Condensed Interim Statements of C |
|
| November 14, 2016 |
EX-99.1 2 v452214ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NeuroDerm Announces Third Quarter 2016 Financial Results - Company to host conference call and webcast today at 8:30 a.m. ET - REHOVOT, Israel – November 10, 2016 – NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the third qu |
|
| September 29, 2016 |
NeuroDerm 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l |
|
| September 29, 2016 |
Exhibit 99.2 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications REHOVOT, Israel, September 29, 2016 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today anno |
|
| September 29, 2016 |
Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm?s ND0612 Mini-Pump Delivery System Successfully Used by Parkinson?s Disease Patients in Home Setting - Data Presented at 4th World Parkinson Congress - REHOVOT, Israel, September 22, 2016 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing |
|
| August 30, 2016 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Ad |
|
| August 30, 2016 |
EXHIBIT 99.2 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update - Company to host conference call and webcast today at 8:30 a.m. ET - REHOVOT, Israel ? August 25, 2016 ? NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drugs |
|
| August 30, 2016 |
EXHIBIT 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson?s Disease - Number of patients targeted for enrollment reduced based on observed and anticipated treatment effect - REHOVOT, Israel, August 25, 2016 ? NeuroDerm Ltd. (Nasdaq: NDRM |
|
| July 28, 2016 |
NeuroDerm 6-K (Current Report of Foreign Issuer) 6-K 1 v4452366k.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel |
|
| July 28, 2016 |
EX-99.2 3 v445236ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Issuance of a New U.S. Patent for Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions REHOVOT, Israel, July 27, 2016 – NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceut |
|
| July 28, 2016 |
Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Start of Bioequivalence Trial in Healthy Volunteers of ND0701, a New Continuous Subcutaneously Delivered Apomorphine Product Candidate for the Treatment of Advanced Parkinson?s Disease - ND0701 complements the company?s product pipeline for the treatment of adv |
|
| July 7, 2016 |
Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Additions to Management Team REHOVOT, Israel, July 6, 2016 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the appointments of Tami Yardeni as Chief Operating |
|
| July 7, 2016 |
NeuroDerm 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Addr |
|
| July 1, 2016 |
NeuroDerm FORM 8-K (Current Report of Foreign Issuer) 6-K 1 v4434666-k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, I |
|
| July 1, 2016 |
Exhibit 99.2 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces ND0612H Achieves Comparable Pharmacokinetics to DUODOPA? in Head-To-Head Pilot PK Comparison Trial - Company to Proceed with Regulatory Development of ND0612H Based on PK Similarity for the Treatment of Parkinson?s Disease in EU ? - Company to Host Conference C |
|
| July 1, 2016 |
Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Presents Three Posters at the 20th International Congress of Parkinson?s Disease and Movement Disorders - Data Presented in the Posters Included Data on the Company?s New Apomorphine Product Candidate (ND0701) as well as Study Design of the First ND0612H Efficacy Trial ( |
|
| July 1, 2016 |
Exhibit 99.3 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Start of U.S. Patient Enrollment in Trial 006, a Phase II Trial of ND0612H for Advanced Parkinson?s Disease - Expansion of Ongoing Multicenter International Trial to Sites in the U.S. to Support Broad Regulatory Development Strategy of Subcutaneously Delivered |
|
| June 15, 2016 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2016 Commission File Number: 001-36737 NEURODERM LTD. (Translation of Registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 9 |
|
| May 26, 2016 |
EXHIBIT 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces First Quarter 2016 Financial Results - Company to Host Conference Call and Webcast Today at 8:30 a.m. ET - REHOVOT, Israel ? May 26, 2016 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) |
|
| May 26, 2016 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Addre |
|
| May 17, 2016 |
EX-99.1 2 v439591exh99x1.htm EXHIBIT 99.1 Exhibit 99.1 NEURODERM LTD. 3 Pekeris St., Rabin Science Park, Rehovot 7670212, Israel May 5, 2016 NOTICE OF 2016 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 14, 2016 Dear NeuroDerm Ltd. Shareholders: We cordially invite you to attend the 2016 Annual General Meeting of Shareholders, or the Meeting, of NeuroDerm Ltd., or the Company, to be hel |
|
| May 17, 2016 | ||
| May 17, 2016 |
NeuroDerm 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2016 Commission File Number 001-36737 NEURODERM LTD. (Translation of Registrant?s name into English) Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel (Address of Principal Execu |
|
| May 9, 2016 |
NeuroDerm 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Addre |
|
| May 9, 2016 |
Exhibit 99.1 NeuroDerm Announces Patient Enrollment in Long-Term Safety Trial of ND0612 for Parkinson’s Disease - Trial to Provide Safety Data to Support U.S. and EU Regulatory Applications of Liquid Levodopa/Carbidopa Lead Product Candidate – REHOVOT, Israel, May 9, 2016 – NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diso |
|
| May 9, 2016 |
Exhibit 99.1 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NEURODERM Announces 2016 ANNUAL General Meeting of Shareholders REHOVOT, ISRAEL, May 5, 2016 (GLOBE NEWSWIRE)?NeuroDerm Ltd. (NASDAQ: NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will hold its 2016 Annu |
|
| May 9, 2016 |
NeuroDerm 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2016 Commission File Number 001-36737 NEURODERM LTD. (Translation of Registrant?s name into English) Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel (Address of Principal Execu |
|
| April 22, 2016 |
Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Removal of FDA Import Alert of Infusion Pumps Used in ND0612 Clinical Trials REHOVOT, Israel ? April 22, 2016 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced th |
|
| April 22, 2016 |
NeuroDerm 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Add |
|
| April 14, 2016 |
NEURODERM LTD. April 14, 2016 Securities and Exchange Commission Division of Corporation Finance 110 F Street, N.E. Washington, D.C. 20549 Re: NeuroDerm Ltd. Registration Statement on Form F-3 (File No. 333-210496) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, NeuroDerm Ltd. (the ?Company?) hereby requests acceleration of the effective date of its Registr |
|
| April 4, 2016 |
Exhibit 99.1 Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Fourth Quarter and Full Year 2015 Financial Results and Provides a Corporate Update - Company to Host Conference Call and Webcast Today at 8:30 a.m. ET - REHOVOT, Israel ? March 31, 2016 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company d |
|
| April 4, 2016 |
NeuroDerm 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2016 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Add |
|
| March 31, 2016 |
As filed with the Securities and Exchange Commission on March 31, 2016 Registration No. |
|
| March 31, 2016 |
As filed with the Securities and Exchange Commission on March 31, 2016 Registration No. |
|
| March 31, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E |
|
| March 31, 2016 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-200331 and No. 333-205485) of NeuroDerm Ltd. of our report dated March 29, 2016, relating to the financial statements of NeuroDerm Ltd., which appears in this Form 20-F. Tel Aviv, Israel /s/ Kesselman & Kesselman March 30, 201 |
|
| March 31, 2016 |
Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Roy Golan, certify that: 1. I have reviewed this annual report on Form 20-F of NeuroDerm Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| March 31, 2016 |
Exhibit 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(b)/RULE 15d-14(b) UNDER THE EXCHANGE ACT AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of NeuroDerm Ltd. (the ?Company?) on Form 20-F for the fiscal year ended December 31, 2015 as filed with the Se |
|
| March 31, 2016 |
Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Oded Lieberman, certify that: 1. I have reviewed this annual report on Form 20-F of NeuroDerm Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a materi |
|
| March 7, 2016 |
NDRM / NeuroDerm Ltd. / Capital Point Ltd. - SC 13G/A Passive Investment SC 13G/A 1 zk1618168.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, per value NIS 0.01 per share (T |
|
| February 17, 2016 |
NDRM / NeuroDerm Ltd. / Wascher Uwe S. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, Par Value NIS 0.01 (Title of Class of Securities) M74231 107 (CUSIP Number) December 31, 2015 (Date of E |
|
| February 16, 2016 |
NDRM / NeuroDerm Ltd. / Redmile Group, LLC Passive Investment SC 13G 1 neuroderm13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M74231107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) ý Rule 13d-1(b) ¨ Rul |
|
| February 12, 2016 |
NeuroDerm SC 13G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 zk1618010.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, Par Value NIS 0.01 (Title of Class of Securities) M74231 107 (CUSIP Nu |
|
| January 20, 2016 |
NDRM / NeuroDerm Ltd. / SCOPIA CAPITAL MANAGEMENT LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 30, 2015 |
Exhibit 99.1 NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinson?s Disease First Clinical Efficacy Study Investigating ND0612H Subcutaneously Delivered Liquid Levodopa/Carbidopa for the Treatment of Advanced Parkinson's Disease REHOVOT, Israel, December 30, 2015 - NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs |
|
| December 30, 2015 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2015 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l ( |
|
| November 17, 2015 |
NDRM / NeuroDerm Ltd. / SCOPIA CAPITAL MANAGEMENT LP Passive Investment SC 13G 1 d690362413-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M74231107 (CUSIP Number) October 6, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 12, 2015 |
Exhibit 99.1 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Third Quarter 2015 Financial Results - Company to host conference call and webcast today at 8:30 a.m. ET - REHOVOT, Israel ? November 11, 2015 ? NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) di |
|
| November 12, 2015 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2015 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l ( |
|
| November 12, 2015 |
Exhibit 99.2 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Streamlined U.S. Development Plan Following FDA Feedback on ND0612H and ND0612L for the Treatment of Parkinson?s Disease ? Based on FDA input, NeuroDerm is not required to conduct its largest Phase III pivotal trial of 360 patients ? ? Company to host conference call |
|
| November 2, 2015 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2015 Commission File Number: 001-36737 NEURODERM LTD. (Translation of Registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 ( |
|
| October 6, 2015 |
Exhibit 99.2 |
|
| October 6, 2015 |
Exhibit 99.1 NEURODERM LTD. 3 Pekeris St., Rabin Science Park, Rehovot 7670212, Israel September 24, 2015 NOTICE OF 2015 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 29, 2015 Dear NeuroDerm Ltd. Shareholders: We cordially invite you to attend the 2015 Annual General Meeting of Shareholders, or the Meeting, of NeuroDerm Ltd., or the Company, to be held at 3:00 p.m. (Israel time) on |
|
| October 6, 2015 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2015 Commission File Number: 001-36737 NEURODERM LTD. (Translation of Registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8 |
|
| September 25, 2015 |
NeuroDerm 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2015 Commission File Number 001-36737 NEURODERM LTD. (Translation of Registrant?s name into English) Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel (Address of Principal |
|
| September 25, 2015 |
Exhibit 99.1 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NEURODERM Announces 2015 ANNUAL General Meeting of Shareholders REHOVOT, ISRAEL, September 24, 2015 (GLOBE NEWSWIRE)—NeuroDerm Ltd. (NASDAQ: NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will hold its 20 |
|
| September 17, 2015 |
NDRM / NeuroDerm Ltd. / Capital Point Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, per value NIS 0.01 per share (Title of Class of Securities) M7423 |
|
| August 12, 2015 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2015 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Ad |
|
| August 6, 2015 |
Exhibit 99.1 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Second Quarter 2015 Financial Results and Provides Corporate Update - Company to host conference call and webcast today at 8:30 a.m. ET - REHOVOT, Israel – August 6, 2015 – NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drugs for cen |
|
| August 6, 2015 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2015 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Ad |
|
| July 17, 2015 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-205490 PROSPECTUS 3,934,520 Shares NeuroDerm Ltd. Ordinary Shares We are offering 3,934,520 ordinary shares. Our ordinary shares are listed on the NASDAQ Global Market under the symbol ?NDRM.? On July 15, 2015, the last reported sales price of our ordinary shares on the NASDAQ Global Market was $17.31 per share. We are an ?emerging growth compa |
|
| July 15, 2015 |
As filed with the Securities and Exchange Commission on July 15, 2015 Registration No. |
|
| July 13, 2015 |
July 13, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 13, 2015 |
3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 July 13, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS NeuroDerm Ltd. (CIK No. 0001598696) Registration Statement on Form F-1 (File No. 333-205490) Ladies and Gentlemen: Pursuant |
|
| July 13, 2015 |
NeuroDerm Ltd. [ ] Ordinary Shares (Par Value NIS 0.01 Per Share) UNDERWRITING AGREEMENT Exhibit 1.1 NeuroDerm Ltd. [ ] Ordinary Shares (Par Value NIS 0.01 Per Share) UNDERWRITING AGREEMENT [ ], 2015 JEFFERIES LLC COWEN AND COMPANY, LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o COWEN AND COMPANY, LLC 599 Lexington Avenue, 27th Floor New York, New York 10022 Ladies and Gentlemen: Introductory. NeuroDerm Ltd., a comp |
|
| July 13, 2015 |
As filed with the Securities and Exchange Commission on July 13, 2015 Registration No. |
|
| July 2, 2015 |
As filed with the Securities and Exchange Commission on July 2, 2015 Registration No. |
|
| July 2, 2015 |
NeuroDerm AMENDMENT TO FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2015 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Ad |
|
| July 2, 2015 |
Exhibit 99.1 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NEURODERM LTD. STATEMENTS OF FINANCIAL POSITION (U.S. dollars in thousands) December 31, March 31, 2014 2015 Assets: Current Assets: Cash and cash equivalents $ 43,238 $ 15,425 Short- term bank deposits - 23,524 Prepaid expenses and receivables 506 904 43,744 39,853 Non-Current Assets: Res |
|
| July 2, 2015 |
As filed with the Securities and Exchange Commission on July 2, 2015 Registration No. |
|
| May 27, 2015 |
Exhibit 99.1 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces First Quarter 2015 Financial Results and Provides Corporate Update - Company to host conference call and webcast today at 8:30 a.m. ET - REHOVOT, Israel ? May 27, 2015 ? NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drugs for centra |
|
| May 27, 2015 |
NeuroDerm 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2015 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Addre |
|
| May 8, 2015 |
Exhibit 99.1 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Lifting of FDA Clinical Hold on ND0612, a Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson?s Disease ND0612H and ND0612L U.S. Clinical Development Cleared to Proceed REHOVOT, Israel ? May 8, 2015 - NeuroDerm Ltd. (NASDAQ: NDRM), a clinical-st |
|
| May 8, 2015 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2015 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant?s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Addre |
|
| April 28, 2015 |
Exhibit 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(b)/RULE 15d-14(b) UNDER THE EXCHANGE ACT AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of NeuroDerm Ltd. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2014 as filed with the Se |
|
| April 28, 2015 |
Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Roy Golan, certify that: 1. I have reviewed this annual report on Form 20-F of NeuroDerm Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| April 28, 2015 |
Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Oded Lieberman, certify that: 1. I have reviewed this annual report on Form 20-F of NeuroDerm Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a materi |
|
| April 28, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) 20-F 1 v40791320f.htm FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION |
|
| April 28, 2015 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-200331) of NeuroDerm Ltd. of our report dated April 21, 2015, relating to the financial statements of NeuroDerm Ltd., which appears in this annual report on Form 20-F. Tel Aviv, Israel /s/ Kesselman & Kesselman April 28, 2015 K |
|
| April 3, 2015 |
NEURODERM LTD. CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION (U.S. dollars in thousands) EXHIBIT 99.1 NeuroDerm Announces Fourth Quarter and 2014 Fiscal Year Financial Results and Provides a Corporate Update REHOVOT, Israel. ? April 2, 2015 ? NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014. ?We made signific |
|
| April 3, 2015 |
NeuroDerm FORM 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2015 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (Add |
|
| February 24, 2015 |
NDRM / NeuroDerm Ltd. 6-K - Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2015 Commission File Number: 001-36737 NEURODERM LTD. (Translation of Registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 ( |
|
| February 24, 2015 |
NDRM / NeuroDerm Ltd. / Hambrecht Jurgen - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, Par Value NIS 0.01 (Title of Class of Securities) M74231 107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires F |
|
| February 17, 2015 |
NDRM / NeuroDerm Ltd. / Cabilly Shmuel - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, Par Value NIS 0.01 (Title of Class of Securities) M74231 107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires F |
|
| February 17, 2015 |
NDRM / NeuroDerm Ltd. / Wascher Uwe S. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, Par Value NIS 0.01 (Title of Class of Securities) M74231 107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires F |
|
| February 17, 2015 |
NDRM / NeuroDerm Ltd. / Taub Robert - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 NeuroDerm Ltd. (Name of Issuer) Ordinary Shares, Par Value NIS 0.01 (Title of Class of Securities) M74231 107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires F |
|
| February 17, 2015 |
CCU / Compania Cervecerias Unidas S.A. / Capital Point Ltd. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 NeuroDerm Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) M74231 107 (CUSIP Number) December 31, 2014 Date of Event Which Requires Filing of the Statement Check the appropriate box to designate the r |
|
| January 28, 2015 |
NDRM / NeuroDerm Ltd. 6-K - Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2015 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (A |
|
| January 28, 2015 |
Exhibit 99.2 NEURODERM LTD. PROXY FOR AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2015 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Ronen Bezalel and David S. Glatt, and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to |
|
| January 28, 2015 |
Exhibit 99.1 NEURODERM Ltd. 3 Pekeris St., Rabin Science Park, Rehovot 7670212, Israel January 28, 2015 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2015 Dear NeuroDerm Ltd. Shareholders: We cordially invite you to attend an Extraordinary General Meeting of Shareholders, or the Meeting, of NeuroDerm Ltd., or the Company, to be held at 3:00 p.m. (Israel time) o |
|
| January 20, 2015 |
NDRM / NeuroDerm Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2015 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l (A |
|
| January 20, 2015 |
Exhibit 99.1 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NEURODERM Announces EXTRAORDINARY General Meeting of Shareholders FOR RATIFICATION OF ELECTION OF EXTERNAL DIRECTORS AND ADOPTION OF COMPENSATION POLICY REHOVOT, ISRAEL, January 19, 2015 (GLOBE NEWSWIRE)—NeuroDerm Ltd. (NASDAQ: NDRM), a clinical-stage pharmaceutical company developing dr |
|
| December 30, 2014 |
Exhibit 99.1 3 Pekeris St., Rabin Science Park, Rehovot 7670212, ISRAEL. Tel: 972-8-9462729, Fax: 972-8-9461729 NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease REHOVOT, Israel - December 30, 2014 - NeuroDerm Ltd. (NASDAQ: NDRM), a clinical-stage pharmaceut |
|
| December 30, 2014 |
NDRM / NeuroDerm Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2014 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l ( |
|
| December 18, 2014 |
NDRM / NeuroDerm Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2014 Commission File Number: 001-36737 NeuroDerm Ltd. (Translation of registrant’s name into English) NeuroDerm Ltd. Ruhrberg Science Building 3 Pekeris St. Rehovot 7670212, Israel +972 (8) 946-2729l ( |
|
| December 18, 2014 |
NeuroDerm Announces Third Quarter 2014 Financial Results and Provides a Corporate Update Exhibit 99.1 NeuroDerm Announces Third Quarter 2014 Financial Results and Provides a Corporate Update REHOVOT, Israel. – December 18, 2014 – NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the third quarter ended September 30, 2014 and provided a corporate update. Recent Highlig |
|
| November 18, 2014 |
NDRM / NeuroDerm Ltd. S-8 - - S-8 As filed with the Securities and Exchange Commission on November 18, 2014 Registration No. |
|
| November 17, 2014 |
4,500,000 Shares NeuroDerm Ltd. Ordinary Shares Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. |
|
| November 14, 2014 |
NeuroDerm Ltd. Pricing Term Sheet—November 13, 2014 4,500,000 Ordinary Shares Issuer Free Writing Prospectus dated November 14, 2014 Supplementing the Preliminary Prospectus dated November 7, 2014 Registration Statement No. |
|
| November 10, 2014 |
NDRM / NeuroDerm Ltd. 8-A12B - - 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 NeuroDerm Ltd. (Exact name of registrant as specified in charter) State of Israel (State or other jurisdiction of incorporation or organization) Not Applicable (I.R.S. Employer Identification No. |
|
| November 10, 2014 |
NDRM / NeuroDerm Ltd. CORRESP - - November 10, 2014 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D. |
|
| November 10, 2014 |
NDRM / NeuroDerm Ltd. CORRESP - - November 10, 2014 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Christina De Rosa 100 F Street, N. |
|
| November 7, 2014 |
NDRM / NeuroDerm Ltd. CORRESP - - November 7, 2014 VIA EDGAR SUBMISSION AND HAND DELIVERY Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 7, 2014 |
NDRM / NeuroDerm Ltd. F-1/A - - F-1/A Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on November 7, 2014. |
|
| November 3, 2014 |
Exhibit 10.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of , 2014, is entered into by and between NeuroDerm Ltd., an Israeli company whose address is Ruhrberg Science Building, 3 Pekeris St., Rehovot 7670212, Israel (the “Company”), and the undersigned Director or Officer of the Company whose name appears on the signature page hereto (the “Indemnitee”). WH |
|
| November 3, 2014 |
THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY ARTICLES OF ASSOCIATION NEURODERM LTD. Exhibit 3.3 THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY ARTICLES OF ASSOCIATION OF NEURODERM LTD. PRELIMINARY 1. DEFINITIONS; INTERPRETATION. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless the subject or context requires otherwise. “Articles” shall mean these Articles of Association, as amended f |
|
| November 3, 2014 |
Exhibit 99.2 Consent of Director Nominee NeuroDerm Ltd. (the “Company”) has filed a Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the proposed initial public offering of its ordinary shares. In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, t |
|
| November 3, 2014 |
Exhibit 1.1 NeuroDerm Ltd. [Number of Shares] Ordinary Shares (Par Value NIS 0.01 Per Share) UNDERWRITING AGREEMENT [Date] JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. NeuroDerm Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes to issue and sell t |
|
| November 3, 2014 |
Exhibit 4.1 FORM OF SHARE CERTIFICATE NeuroDerm Ltd. Number Shares NDRM CUSIP: M74231 107 See Reverse for Certain Definitions NEURODERM LTD. INCORPORATED UNDER THE LAWS OF THE STATE OF ISRAEL THIS CERTIFIES that is the Registered Holder of FULLY PAID AND NON-ASSESSABLE ORDINARY SHARES OF NIS 0.01 PAR VALUE EACH of NeuroDerm Ltd. transferable on the books of the Company by the holder hereof in pers |
|
| November 3, 2014 |
NEURODERM LTD. 2014 INCENTIVE COMPENSATION PLAN Exhibit 10.5 NEURODERM LTD. 2014 INCENTIVE COMPENSATION PLAN NeuroDerm Ltd., an Israeli corporation (the “Company”), has adopted the NeuroDerm Ltd. 2014 Incentive Compensation Plan (the “Plan”) for the benefit of non-employee directors of the Company and officers and eligible employees and consultants of the Company and any Affiliates (as each term is defined below), as follows: ARTICLE I. ESTABLI |
|
| November 3, 2014 |
NDRM / NeuroDerm Ltd. CORRESP - - November 3, 2014 VIA EDGAR SUBMISSION AND HAND DELIVERY Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 3, 2014 |
NDRM / NeuroDerm Ltd. F-1/A - - F-1/A Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on November 3, 2014. |
|
| November 3, 2014 |
Amendments to Existing Articles of Association of NeuroDerm Ltd. Prior to Closing of the Offering Exhibit 3.2 Amendments to Existing Articles of Association of NeuroDerm Ltd. Prior to Closing of the Offering The text of paragraph (a) of Article 6 of the Amended and Restated Articles of Association of NeuroDerm Ltd. is hereby amended and restated in its entirety to read as follows: (a) The share capital of the Company is 1,516,244 New Israeli Shekels, which is divided into the following numbers |
|
| November 3, 2014 |
Exhibit 99.1 Consent of Director Nominee NeuroDerm Ltd. (the “Company”) has filed a Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the proposed initial public offering of its ordinary shares. In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, t |
|
| November 3, 2014 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT EX-10.1 7 a2221700zex-101.htm EX-10.1 EXHIBIT 10.1 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 3 2. Registration Rights 6 2.1. Demand Registration 6 2.2. Company Registration 8 2.3. Underwriting Requirements 9 2.4. Obligations of the Company 11 2.5. Furnish Information 13 2.6. Expenses of Registration 13 2.7. Delay of Registration 13 2.8. Indemnification |
|
| October 6, 2014 |
NDRM / NeuroDerm Ltd. CORRESP - - begin 644 filename2.pdf M)5!$1BTQ+C4-)>+CS],-"C@S(#`@;V)J#3P\+TQI;F5A%LX,R`S M-UTO26YF;R`X,B`P(%(O3&5N9W1H(#$S-R]0 M8F)D8!!@8&)@8&8'D0R!8+(91#)U@DA&;S#Y!4R>!HOW@DBN%K!*$[!($E@V M#T3V,(%(DU`DC%[`XA=/Q=$BJ\#B>A6@=C%?T&D:`8G`BP";-!I"I(/6.K M%(C=U`XB-4#F,\I.!*L$N>K/FVD,3$`W/P+;SL"(DS/P'3J-T"``0!M1!AN M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@ M("`-"C$Q.2`P(&]B:@T\/"]&:6QT97(O1FQA=&5 |
|
| October 6, 2014 |
NDRM / NeuroDerm Ltd. CORRESP - - October 6, 2014 VIA HAND DELIVERY AND EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 15, 2014 |
NDRM / NeuroDerm Ltd. CORRESP - - September 15, 2014 VIA EDGAR & HAND DELIVERY Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 15, 2014 |
NeuroDerm Ltd. 2007 SHARE OPTION PLAN EXHIBIT 10.4 NeuroDerm Ltd. 2007 SHARE OPTION PLAN 1. PURPOSE The purpose of this Share Option Plan is to secure for NeuroDerm Ltd. and its shareholders the benefits arising from ownership of share capital by employees, officers directors and consultants of the Company and its Affiliates (as defined below), who are expected to contribute to the Company’s future growth and success. 2. DEFINITIONS 2 |
|
| September 15, 2014 |
NDRM / NeuroDerm Ltd. F-1 - - F-1 F-1 1 a2220625zf-1.htm F-1 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on September 15, 2014. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroDerm Ltd. (Exact Name of Regis |
|
| September 15, 2014 |
Exhibit 10.3 English summary of Principal Terms of Lease Agreement, dated February 2, 2014, by and between Ruhrberg Contracting and Investments (1963) Ltd. (the “Landlord”), as landlord, and NeuroDerm Ltd. (the “Company”), as tenant (the “Lease”). The Lease · Premises Covered by the Lease: Approximately 538 square meters (or 5,790 square feet) and 15 parking spaces, located in Rabin Science Park, |
|
| September 15, 2014 |
EXHIBIT 21.1 List of Subsidiaries None. |
|
| September 15, 2014 |
EXHIBIT 3.1 THE COMPANIES LAW - 1999 COMPANY LIMITED BY SHARES AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF NEURODERM LTD. 1. Company Name The name of the Company is Neuroderm Ltd. (the “Company”). 2. Purpose The purpose of the Company is to engage in any lawful act or activity for which companies may be organized under the Israeli Companies Law, 1999, as may be amended from time to time (the “ |
|
| June 17, 2014 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As confidentially submitted to the Securities and Exchange Commission on June 17, 2014. |
|
| June 17, 2014 |
June 17, 2014 VIA EDGAR & HAND DELIVERY Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 23, 2014 |
May 23, 2014 VIA EDGAR & HAND DELIVERY Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 23, 2014 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 23, 2014. |
|
| April 11, 2014 |
NeuroDerm Ltd. 2007 SHARE OPTION PLAN EXHIBIT 10.4 NeuroDerm Ltd. 2007 SHARE OPTION PLAN 1. PURPOSE The purpose of this Share Option Plan is to secure for NeuroDerm Ltd. and its shareholders the benefits arising from ownership of share capital by employees, officers directors and consultants of the Company and its Affiliates (as defined below), who are expected to contribute to the Company’s future growth and success. 2. DEFINITIONS 2 |
|
| April 11, 2014 |
EXHIBIT 3.1 Amended Articles — January 2014 THE COMPANIES LAW - 1999 COMPANY LIMITED BY SHARES AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF NEURODERM LTD. 1. Company Name The name of the Company is Neuroderm Ltd. (the “Company”). 2. Purpose The purpose of the Company is to engage in any lawful act or activity for which companies may be organized under the Israeli Companies Law, 1999, as may be |
|
| April 11, 2014 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As confidentially submitted to the Securities and Exchange Commission on April 11, 2014. |
|
| April 11, 2014 |
Exhibit 10.3 English summary of Principal Terms of Lease Agreement, dated February 2, 2014, by and between Ruhrberg Contracting and Investments (1963) Ltd. (the “Landlord”), as landlord, and NeuroDerm Ltd. (the “Company”), as tenant (the “Lease”). The Lease · Premises Covered by the Lease: Approximately 538 square meters (or 5,790 square feet) and 15 parking spaces, located in Rabin Science Park, |
|
| April 11, 2014 |
EXHIBIT 21.1 List of Subsidiaries None. |
